Aspire Biopharma Holdings (ASBP) Cost of Revenue (2025 - 2026)

Aspire Biopharma Holdings' (ASBP) quarterly Cost of Revenue came in at $50818.0 in Q2 2026, up 124.83% quarter-over-quarter from $22603.0 in Q1 2026.

Analysis

Aspire Biopharma Holdings (ASBP) Cost of Revenue (2025 - 2026) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has reported Cost of Revenue for 2 consecutive years, with $50818.0 the latest figure, recorded in Q2 2026.

On a quarterly basis, Cost of Revenue changed N/A year-over-year to $50818.0 in Q2 2026; TTM through Jun 2026 was $79739.0, a N/A change from a year earlier, with the FY2025 full-year figure at $6318.0, changed N/A from the prior year.
Cost of Revenue was $50818.0 for Q2 2026 at Aspire Biopharma Holdings, up from $22603.0 in the prior quarter.
Over five years, Cost of Revenue peaked at $50818.0 in Q2 2026 and troughed at $1057.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn	2.81 Bn
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn	1.58 Bn
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn	489.20 Mn
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn	360.70 Mn
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn	93.00 Mn
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn	145.00 Mn
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn	298.26 Mn
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn	776.90 Mn
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn	284,000.00
10	Aspire Biopharma Holdings	64.13 Mn	51.96 Mn	-30,086.00	50,818.00

Historic Data

Download Data